dementia

shutterstock_189857270

Introduction

Dementia is a syndrome resulting from brain disease, characterised by a global cognitive decline, which may include disturbances of thinking, memory, comprehension and orientation.

Symptoms can vary, depending on the cause, but memory difficulties are often the first problem to be noticed. There is sometimes a change in personality with alterations in behaviour, termed ‘BPSD’ (behavioural and psychological symptoms of dementia).

There are several types of dementia. We could talk about each in much greater detail, but in summary the most prevalent types are:

  • Alzheimer’s disease (most common form of dementia)
  • Lewy body dementia
  • Vascular dementia
  • Frontotemporal dementia
  • Rarer causes e.g. HIV, vitamin B12 deficiency, etc

What we already know

Screening and diagnosis of dementia has much improved over the last few years, with many areas of the country having a specific ‘memory clinic’ service, although controversy remains about which instrument to use to diagnose dementia.

The management of dementia includes both pharmacological treatment and non-pharmacological considerations (e.g. ensuring the environment is appropriate, providing activity and stimulation and addressing communication needs).

The use of acetylcholinesterase inhibitors has become much more widespread over recent years and, although it is no wonder drug or cure, for some people with Alzheimer’s, it can slow the progression of the disease. NICE guidelines recommend the use of Donepezil, Galantamine or Rivastigmine for mild-moderate Alzheimer’s disease. Mematine is recommended as an option for those with moderate Alzheimer’s disease who cannot tolerate acetylcholinesterase inhibitors, or for those with severe Alzheimer’s disease.

Areas of uncertainty

What actually causes dementia? We know lots of factors and even some genetic changes that are associated with dementia but we know little about the actual direct causes of dementia.

There is also uncertainty about the reason that some people progress from Mild Cognitive Impairment (memory impairment that does not meet diagnostic threshold of dementia) to dementia and how to predict who this will happen to.

What’s in the pipeline

Media reports often hint at a progression towards finding a cure for dementia. In practice we may not be that close, but there are several areas that researchers are working on:

  • Gene therapy
  • A vaccine for dementia
  • The use of stem cells to develop replacement cells lost in dementia

References

Giebel, C. M., Sutcliffe, C., Stolt, M., Karlsson, S., Renom-Guiteras, A., Soto, M., … Challis, D. (2014). Deterioration of basic activities of daily living and their impact on quality of life across different cognitive stages of dementia: a European study. International Psychogeriatrics / IPA, 26(8), 1283–93. doi:10.1017/S1041610214000775 [Abstract]

NICE guidelines CG42 (2015) “Dementia: Supporting people with dementia and their carers in health and social care” [PDF]

Semple, D. and Smyth, R. (eds.) (2013) Oxford Handbook of Psychiatry. 3rd ed. Oxford: Oxford University Press. [Publisher]

Acknowledgement

Written by: Josephine Neale
Reviewed by:
Last updated: Sep 2015
Review due: Sep 2016

Our dementia Blogs

The common core principles for supporting people with dementia

iStock_000008800117XSmall nurse and old woman reading leaflet

The Department of Health has commissioned Skills for Care and Skills for Health to produce new guidance for health and social care professionals who work with people who have dementia. The publication provides guidance for leaders and managers, commissioners and training and education leads to develop a workforce that can create dementia friendly settings. It [read the full story…]

Commitment to review care for people with dementia on antipsychotic medication

AA023233

The Dementia Action Alliance has launched a call to action on the use of antipsychotic drugs for people with dementia: All people with dementia who are receiving antipsychotic drugs should receive a clinical review from their doctor to ensure that their care is compliant with current best practice and guidelines and that alternatives to medication have been [read the full story…]

New diagnostic criteria for Alzheimer’s disease published by US National Institute on Aging

iStock_000016098935XSmall old man eye close up

The US National Institute on Aging and the Alzheimer’s Association have published a new set of guidelines for diagnosing dementia and mild cognitive impairment due to Alzheimer’s disease. All of the papers from the Alzheimer’s and Dementia journal are available online in full-text: Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies [read the full story…]

NICE launch interactive pathways on a range of mental health topics

nhs evidence eye

NICE guidance has sometimes suffered from poor accessibility and usability, and as a result, it has not always been implemented at the coalface as well as it could have been. NICE have responded to this criticism by creating a set of interactive online pathways that bring together all of their content around a specific topic. [read the full story…]

New NICE guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease

nhs evidence eye

The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and memantine is now recommended as an option for managing moderate Alzheimer’s [read the full story…]